Top Stories
Why are Zaggle Prepaid shares falling 10% despite 30% Q4 profit jump? Explained Tata Motors CV Q4 Results: Revenue rises 22% YoY, EBITDA increases 35% Yatharth Hospitals to acquire Gurugram hospital asset for ₹100 crore from RNY healthcare Cipla Q4 Results: Profit falls 55% on a YoY basis, margin contracts sharply Flipkart beats TCS, Infosys as India’s most preferred employer: Blind survey of 1,205 professionals reveals shift Delhi HC upholds ₹144.51 crore deposit order against SpiceJet in Kalanithi Maran case, dismisses review petition Why are Vodafone Idea shares up sharply 8% today? Details here IIFL Finance shares jump 8% after company plans to challenge ₹475 crore tax demand Why are Zaggle Prepaid shares falling 10% despite 30% Q4 profit jump? Explained Tata Motors CV Q4 Results: Revenue rises 22% YoY, EBITDA increases 35% Yatharth Hospitals to acquire Gurugram hospital asset for ₹100 crore from RNY healthcare Cipla Q4 Results: Profit falls 55% on a YoY basis, margin contracts sharply Flipkart beats TCS, Infosys as India’s most preferred employer: Blind survey of 1,205 professionals reveals shift Delhi HC upholds ₹144.51 crore deposit order against SpiceJet in Kalanithi Maran case, dismisses review petition Why are Vodafone Idea shares up sharply 8% today? Details here IIFL Finance shares jump 8% after company plans to challenge ₹475 crore tax demand
AUTHOR

Yash Agarwal

Yash Agarwal is a financial journalist at Business Upturn, covering corporate announcements, market developments, and regulatory filings. A recent commerce graduate, he brings a sharp eye for numbers and a keen interest in India's capital markets and listed companies. Yash is reachable at [email protected]

COVERS
Business Stock Market
LATEST
BUSINESS

Alembic Pharmaceuticals receives USFDA tentative approval for Darolutamide Tablets

Alembic Pharmaceuticals Limited has received tentative approval from the USFDA for Darolutamide Tablets, 300 mg, equivalent to Bayer's Nubeqa.

May 14, 2026
blank
1 … 41 42 43 44 45 … 72